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ABSTRACT 
BACKGROUND 
We conducted a meta-analysis of the randomized evidence to determine the relative merits of 
histopathological outcomes of laparoscopic assisted (LARR) versus open rectal resection (ORR) for 
rectal cancer. 
DATA SOURCES 
A search of PubMed and other electronic databases comparing LARR and ORR between Jan 2000 
and June 2016 was performed. Histopathological variables analyzed included; location of rectal 
tumors; complete and incomplete TME; positive and negative circumferential resection margins (+/-
CRM); positive distal resected margins (+DRM); distance of tumor from DRM; number of lymph 
nodes harvested; resected specimen length; tumor size and perforated rectum. 
RESULTS  
Fourteen RCTs totaling 3843 patients (LARR=2096, ORR= 1747) were analyzed. Comparable effects 
were noted for all these histopathological variables except for the variable perforated rectum which 
favored ORR.  
CONCLUSIONS 
LARR compares favorably to ORR for rectal cancer treatment. However, there is significantly higher 
risk of rectal perforation during LARR compared to ORR. 
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SYNOPSIS 
As there remains concern regarding the equivalence of ORR versus LARR, the objective of 
this meta-analysis was to analyze the histopathological variables of these two surgical 
procedures based on various randomized controlled trials (RCTs) published to date.  
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ABSTRACT 
ABSTRACT 
BACKGROUND 
We conducted a meta-analysis of the randomized evidence to determine the relative merits of 
histopathological outcomes of laparoscopic assisted (LARR) versus open rectal resection 
(ORR) for rectal cancer. 
DATA SOURCES 
A search of PubMed and other electronic databases comparing LARR and ORR between Jan 
2000 and June 2016 was performed. Histopathological variables analyzed included; location 
of rectal tumors; complete and incomplete TME; positive and negative circumferential 
resection margins (+/-CRM); positive distal resected margins (+DRM); distance of tumor 
from DRM; number of lymph nodes harvested; resected specimen length; tumor size; and 
perforated rectum. 
RESULTS  
Fourteen RCTs totaling 3843 patients (LARR=2096, ORR= 1747) were analyzed. 
Comparable effects were noted for all these histopathological variables except for the variable 
perforated rectum which favored ORR.  
CONCLUSIONS 
LARR compares favorably to ORR for rectal cancer treatment. However, there is 
significantly higher risk of rectal perforation during LARR compared to ORR. 
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INTRODUCTION 
In 1991, the first laparoscopic colonic surgery was performed1 and it is now a well-established 
procedure for colonic cancer supported by several well-conducted large-scale randomized 
controlled trials (RCTs). However, laparoscopic assisted rectal resection (LARR) continued 
to be one of the most technically challenging operations in the laparoscopic era and its benefit 
for rectal cancer remains contentious. Contemporary treatment for rectal cancer is based on a 
sharp, meticulous extirpation of the cancer en bloc with its surrounding perirectal lymphatic 
tissue contained within a thin fascial layer, referred to as total mesorectal excision (TME)2. 
The current literature is overwhelmed with technical modifications and pro-con arguments for 
the numerous aspects of LARR and in particular low rectal cancer. However, due to 
anatomical constraints and the complexity of the pelvic surgery, LARR may have limitations 
in performing an adequate oncological resection. Furthermore, concerns about long term 
equivalence of conventional open rectal resection (ORR) versus LARR are still under debate. 
Because of these apprehensions, and the risks involved with local tumor control and 
recurrence in case of inadequate oncological resection, the necessity and objectivity for 
longitudinal data analyses for LARR patients is very crucial. This meta-analysis RCTs was 
undertaken to analyze the histopathological outcome of LARR and ORR for rectal carcinoma.  
 
MATERIALS AND METHODS 
Search strategy and study selection 
RCTs of any size that compared LARR with ORR for rectal carcinoma, and were published in 
full in peer-reviewed journals in the English language between January 1990 and the end of 
June 2016, were included (Table 1). Unpublished studies and abstracts presented at national 
and international meetings were excluded. Trials were identified by conducting a 
comprehensive search of Medline, Embase, Science Citation Index, Current Contents and 
PubMed databases, using medical subject headings (MESH) “proctectomy”, , “anterior 
resection”, “low anterior resection” “rectal resection”, “abdominoperineal resection”, “rectal 
carcinoma”, “rectal cancer”, “rectal tumour or tumor”, “laparoscopic method”, “open 
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method”, ‘‘comparative study”, “prospective studies”, “randomized or randomised controlled 
trials”, “random allocation”, “clinical trial”, “english” and “human”. A manual search of the 
bibliographies of relevant papers was also carried out to identify trials for possible inclusion.  
 
Data Extraction and Methodological Quality 
Data extraction and critical appraisal were carried out by two authors independently (AA and 
MAM). The authors were not blinded to the source of the document or authorship(s) for the 
purpose of data extraction. Standardized data extraction forms were used by authors to 
independently and blindly summarize all the data available in the RCTs3. The data that was 
obtained was entered directly into MS Word tables. Double data entry method was used in 
order to avoid errors in data extraction. The data was compared, and discrepancies were 
addressed with discussion until consensus was achieved. The analysis was prepared in 
accordance with the Preferred Reporting of Systematic Reviews and Meta-Analyses 
(PRISMA) statement3.  Random effects model was used for analysis of all the outcome 
variables. The quality of the RCTs was assessed using Jadad’s scoring system4 where each 
study was allocated a score from zero to five, zero being the lowest quality and five being the 
highest, based on whether the authors had reported the method of randomization, or if the 
participants or the surgeons were blinded to the treatment protocol, and if any withdrawals 
were reported during the study.  
 
Eligibility Criteria 
Two reviewers (AA and MAM) individually considered the abstracts of the identified articles 
for eligibility. Appropriateness was determined by these independent reviewers and by 
discussion in case of inconsistency. RCTs must have reported on at least one clinically 
relevant pathological outcome. Outcomes assessed were those considered to exert influence 
over technical and histopathological aspects of surgical practice and patient management. All 
studies reporting on outcomes of this nature were considered and final analyses were run on 
outcome variables where numbers were sufficient to allow statistical analysis.  
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Inclusion Criteria 
(i) Type of Study: Only RCTs published in full peer-reviewed journals between January 
1990 and June 2016, were included for analysis.  
(ii) Language: Only English language articles were considered for this analysis 
(iii) Type of Intervention: Two different operative approaches i.e. LARR and ORR for 
the elective management of rectal carcinoma (high, mid or low), were being assessed. 
(iv) Type of participants: Adult (>16 years) patients were the target population for this 
meta-analysis 
 
Exclusion Criteria 
(i) Non-randomized controlled trials, duplicated RCTs, unpublished studies and 
abstracts presented at national and international meetings presenting the 
preliminary data were excluded from our analysis, 
(ii) RCTs containing a mixture of colonic and rectal surgical resections i.e. 
CLASSICC trial5, where data on purely rectal resection was either minimal or not 
available and /or could not be separated from the colonic resection patients. This 
was undertaken to prevent contamination of “pure” rectal cancer resection data 
(iii) Emergency surgical cases. 
 
Types of Outcome Measures Analyzed 
The ten outcome variables analyzed included; 
(a) Location of tumor in rectum (high, middle or low) 
(b) Complete total mesorectal excision (TME) 
(c) Incomplete TME 
(d) Positive circumferential resection margins (+ve CRM) 
(e) Negative circumferential resection margins (-ve CRM) 
(f) Negative distal resected margins (-ve DRM) 
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(g) Distance of tumor from DRM 
(h) Number of lymph nodes harvested 
(i) Length of resected sample 
(j) Tumor size 
(k) Perforated rectum 
 
Statistical Analysis and Risk of bias across Studies 
Meta-analyses were performed using odds ratios (ORs) for binary outcome and weighted 
mean differences (WMDs) for continuous outcome measures. The slightly amended estimator 
of OR was used to avoid the computation of reciprocal of zeros among observed values in the 
calculation of the original OR6. Random effects model based on the inverse variance weighted 
method approach was used to combine the data7. Heterogeneity among studies was assessed 
using the Q statistic proposed by Cochran and I2 index introduced by Higgins and Thompson7-
11
. If the observed value of Q was greater than the associated x2 critical value of 0.05, we 
conclude the presence of statistically significance between-studies variation. In order to pool 
continuous data, the mean and standard deviation of each study is required. However, some of 
the published clinical trials did not report the mean and standard deviation, but rather reported 
the size of the trial, the median and range. Using these available statistics, estimates of the 
mean and standard deviation were obtained using formulas proposed by Hozo et al12. Funnel 
plots were created in order to determine the presence of publication bias in the present meta-
analysis. Both total sample size and precision (reciprocal of standard error) were plotted 
against the treatment effects (OR for dichotomous variables and WMD for continuous 
variables)9,13-15. All estimates were obtained using a computer program written in R16. All 
plots were obtained using the metafor-package17. In the case of tests of hypotheses, the paper 
reports p-values for different statistical tests on the study variables. In general, the effect is 
considered to be statistically significant if the p-value is small. If one uses a 5% significance 
level then the effect is significant only if the associated p-value is ≤5%. 
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RESULTS 
Included Studies 
Cross searching of electronic databases yielded a total of 153 abstracts and hand searches of 
reference lists provided a further 6 citations. After exclusion of non-relevant citations, 37 
unique citations of potential relevance were retrieved for review. The process by which these 
citations were excluded is described in Figure 1. There was almost perfect agreement 
(κ=0.99) between the two authors (AA and MAM) regarding inclusion of these RCTs. 
Fourteen RCTs met the inclusion criteria18-31 (Table 1).  
 
Methodological Quality 
In general, the quality of RCTs demonstrated moderate methodological quality based on 
Jadad score4 with an average score of 3 (out of five), with a range of 2 to 4 (Table 1).  
 
Heterogeneity 
The Q test and I2 Index8,11 are commonly used methods in meta-analysis for detecting 
heterogeneity. Significant heterogeneity i.e. I2 index of 50% or more was only present for 
lymph node harvesting and length of DRM (Table 2). 
 
Publication Bias 
Only two funnel plots belonging to lymph node harvesting time and distance of tumor from 
DRM demonstrate asymmetry and thus suggest the presence of publication bias. Funnel plots 
belonging to all other variables failed to show publication bias. However, the number of 
studies included for some of these variables were too few to sensitively detect publication 
bias. 
 
Pathological Outcomes  
Fourteen RCTs18-31 totaling 3843 patients (LARR=2096, ORR=1747) were analyzed.  Only 10 
studies18,19,21-23,27-31 report location of tumor i.e. high, middle or low. There was no difference 
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seen between LARR and ORR in the distribution of these tumors amongst various studies. 
Furthermore, comparable effects were noted for complete TME based on 619,27-31 (OR 0.77, 
95% CI 0.56,1.07, p=0.12) (Fig 2);  incomplete TME based on 6 RCTs19,27-31 (OR 1.15, 95% 
CI 0.83,1.59, p=0.41); positive circumferential resection margin (+CRM) based on 12 
RCTs19-25,27-31 (OR 1.21, 95% CI 0.88,1.67, p=0.24) (Fig 3); negative CRM (-CRM) based on 
12 RCTs19-25,27-31 (OR 0.82, 95% CI 0.60,1.13, p=0.24); positive distal resection margin 
(+DRM) based on 8 RCTs19,25-31 (WMD 1.08, 95% CI 0.42, 2.75, p=0.88) (Fig 4); distance of 
tumor from DRM based on 7 RCTs25-31 (WMD 0.50, 95% CI -1.56, 2.55, p=0.64); lymph 
node harvesting based on 12 RCTs18,20-28,30,31 (WMD -0.30, 95% CI -0.81, 1.41, p=0.59) (Fig 
5); length of resected specimen based on 3 RCTs26,29,30 (WMD 0.60, 95% CI -3.74, 4.95, 
p=0.79); tumor size based on 6 RCTs19,26-30 (WMD -0.73, 95% CI –2.14, 0.67, p=0.31) (Fig 
6); The variable perforated rectum based on 4 RCTs (OR 1.70, 95% CI 1.01,2.88, p=0.05) 
favored ORR (Fig 7). 
 
DISCUSSION 
The purpose of this present meta-analysis was to evaluate the histopathological differences 
between ORR and LARR for rectal cancers. Conventional ORR has been considered the gold 
standard for the excision of rectal carcinoma. However, progress made in the field of 
advanced laparoscopic surgery has encouraged surgeons to undertake LARR for the vast 
majority of rectal cancers. Nevertheless, there remains skepticism regarding its safety and 
efficacy32. This meta-analysis has only included RCTs addressing the subject of ORR vs 
LARR and therefore have excluded the CLASSICC trial5 from its analysis as it addresses 
both colon and rectal surgery. Furthermore, a lot of variables on rectal cancer surgery are 
either missing or included with the colonic resection data33. A recent meta-analysis and 
systematic review on the subject of rectal resection34 unfortunately has included the 
CLASSICC trial5 contaminating some of their data. Furthermore, the authors of this meta-
analysis have included the dataset from an older COREAN RCT35 and COLOR II RCT36. 
Both of these RCTs have published their updated version in 201428 and 201531 respectively 
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and therefore, we have included the latest dataset from these RCTs. Lastly, one of the latest 
RCT from Hong Kong is missing altogether27 in this meta-analysis which is surprising as 
according to the authors they have included all the trials from 1995 to 2016 in the English 
language. All the above issues weaken the reliability and validity of their data.  
 
Total Mesorectal Excision (TME) 
Radicality of rectal cancer depends on three important criteria; (i) TME, (ii) CRM and (iii) 
DRM and proximal resection margins (PRM), which need to be free of tumor cells. TME 
requires dissecting in the bloodless plane between the visceral rectal fascia and the parietal 
fascia, and entails complete removal of the adipose lymphatic tissue surrounding the rectum 
with preservation of the pelvic autonomic nerves. The en bloc resection should have 
proximal, distal and circumferential negative margins2. TME should be 5 cm below the tumor 
for tumor specific total TME for upper rectal cancer, or the entire mesorectal envelope for 
low rectal cancer. TME completeness has become an indicator for good surgical technique as 
it decreases the risk of local recurrence in the pelvis. Therefore, the violation of the 
peritonealized posterior surface of the mesorectum even with negative CRM leads to local 
recurrence in the pelvis34. Arbman et al37 have shown that adopting the technique of TME can 
result in a 20% improvement in the 4-year survival rate, and the Norwegian Rectal Cancer 
Group38 showed a greater than 20% reduction in local recurrence after the introduction of 
TME in a study involving >3,000 patients.  
 
The issue of complete and incomplete TME was reported by 6 studies19,27-31. The pooled data 
for 2570 patients did not show any difference between LARR and ORR for complete TME 
(p=0.12) and incomplete TME (p=0.41) with very low heterogeneity (I2=13.61 and 0.00 
respectively) (Figs 2). This is in contradiction to the recently reported systematic review34 
which showed significantly higher incomplete TME for LARR based on a fewer studies and 
patients suggesting inferiority of LARR compared to ORR from a technical point of view. We 
feel that is not the case. When looking at individual rates of complete TME for all the 
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included RCTs in our analysis, they varied between 60%31 to 100%19 for LARR and 67%31 to 
100% for ORR19. As far as the COLOR II trial31 is concerned, such a low rate of complete 
TME both in LARR and ORR is concerning, however, no explanation by the authors is 
provided. It is entirely possible that some of the participating surgeons were still going 
through the learning curve and/or come from low volume centers. This in turn will translate 
into a high recurrence rate and death amongst patients with incomplete TME in the future. A 
longitudinal long term analysis of their data31 regarding recurrence free survival and overall 
survival is keenly awaited to address this issue.  
 
Circumferential Resection Margins (CRM) 
CRM is defined as >1mm between the deepest extent of tumor invasion into the mesorectal 
fat and the inked surface on the fixed specimen29,30. Others have described positive CRM if 
malignant cells were found at microscopy at a distance of <2 mm between the outermost part 
of the tumor and the CRM or between lymph nodes bearing tumor cells and the CRM36. Clear 
CRM is therefore crucial in preventing local recurrence. Berbick et al39 showed a significantly 
higher proportion (38.2%) of CRM-positive patients developing local recurrence than CRM-
negative ones (10.0%). It is now well documented that a positive CRM even in the presence 
of complete TME is considered a biological marker for poor prognosis40.  
 
The issue of positive and negative CRM was addressed by 12 RCTs18-25,27,28,30,31. Positive 
CRMs were noted in 127/1801 (7%) specimens in LARR and 81/1496 (5.4%) in ORR. Based 
on pooled data, there was no statistical difference between the two groups (p=0.24) with very 
low heterogeneity (I2 = 4.88%) (Fig 3). Similarly, 12 studies18-25,27,28,30,31 reported on negative 
CRM; 1674/1801 (92.9%) specimens in LARR and 1415/1496 (94.6%) specimens in ORR 
had negative CRMs. Once again, the pooled data revealed no significant difference between 
the two procedures (p=0.24) and very low heterogeneity (I2 = 4.88%), proving that LARR is 
equivalent to ORR in obtaining oncological radicality by well-trained colorectal surgeons30,31. 
In larger series24,28-31 enrolling at least 100 patients in each arm, the positive CRM rate varied 
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between 2.9%28 to 12%30 for LARR and 2.9%24,29 to 10%31 for ORR. This issue of CRM may 
be confounded by the cutoff threshold of 1 mm or 2 mm clear margins and preoperative 
therapy with either chemotherapy +/- radiotherapy. The best results were obtained by Jeong et 
al28 who showed a +ve CRM rate of 2.9% for LARR and 4.1% for ORR despite the fact that 
they used the positive margin as ≤1 mm. However, 100% of their patients had preoperative 
chemotherapy which may have resulted in tumor shrinkage. In Bonjer RCT31 where almost 
60% of patients received preoperative radiotherapy, the +ve CRM was much higher; 9.5% for 
LARR and 10% for ORR and their 3-year locoregional recurrence rate is similar; 9.7% for 
LARR and 10.1% for ORR. Fleshman et al30 seem to have a much higher rate of +ve CRM 
(12% LARR; 7.6% ORR) based on a cutoff point of ≤1 mm even though over 90% of their 
patients received preoperative chemoradiation. Their RCT showed ORR to be much superior 
to its LARR counterpart in achieving -ve CRM. Stevenson et al29 achieved a much higher -ve 
CRM for LARR (93%) and ORR (97%) despite the fact that only 50% of their patients in 
both arm received radiotherapy but no chemotherapy. However, the worst results were 
obtained in Pechlivanides et al RCT21 where unacceptable positive CRM rates of 23.5% were 
reported for LARR and 25.6% for ORR suggesting either poor surgical technique and/or 
inexperienced surgeons exposing patients to an unnecessary high recurrence rate and death in 
the future.  
 
Distal Resection Margin (DRM) 
The guarantee of a negative DRM is vital in rectal cancer as it signifies a reduced risk of local 
recurrence; therefore, adequate length of the DRM is considered paramount. However, “what 
is the shortest DRM length” is contentious? According to Bujko et al41 subclinical distal 
bowel intramural spread is present within 1 cm distally from visible rectal cancer in a 
substantial proportion of patients. The adequacy of the DRM is dependent on both the risk for 
intramural tumor spread and on the distal mesorectal lymphatic spread, where the role of 
TME becomes important. However, the use of preoperative chemoradiotherapy may lead to 
tumor regression and treatment of microscopic disease, facilitating complete tumor resection 
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with <1 cm bowel margin in patients who are otherwise candidates for abdominoperineal 
resection (APR). Norwegian Colorectal Cancer Registry42 analyzed the data on 3571 patients 
with DRM information treated by anterior resection between 1993 and 2004. Of these, 3342 
(93.5%) patients had not received preoperative radiotherapy. The DRM was measured on 
fixed specimens. The 5-year local recurrence rate was 14.5% for patients with a DRM of 0-10 
mm compared to 9.6% for patients with a DRM of 11-20 mm, 8.9% for a DRM of 21-30 mm, 
7.0% for a DRM of 31-40 mm, 7.7% for a DRM of 41-50 mm and 8.7% for a DRM of > 50 
mm. After adjustment for other independent prognostic factors, a DRM of 0-10 mm was 
found to have significant impact on local recurrence. The DRM had no impact on distant 
metastases or overall survival. The authors concluded that for rectal cancer patients treated 
without radiotherapy, a DRM of > 10 mm is recommended.  
 
A recent study from Korea43 analyzed 376 sphincter-saving resection for rectal 
adenocarcinoma and pre- or postoperative CRT between 2000 and 2006. No significant 
differences in local recurrence (9.8 versus 7.3 %; P = 0.324) and systemic recurrence (16.4 
versus 18.7 %; P = 0.731) were observed in patients with DRMs of ≤5 and >5 mm, 
respectively. Another study by Hong et al44 similarly showed that a DRM of < 1 cm did not 
impair the oncologic outcomes of rectal cancer patients.  
 
For this meta-analysis, DRM was considered negative if it was ≥ 1 mm. Eight RCTs19,25-31 
reported on the status of DRM in the LARR and ORR. There were 7/1052 (0.66%) patients in 
the LARR group and 6/1032 (0.58 %) patients in the ORR group who had a positive DRM. 
The pooled data showed comparable outcomes for both these groups (p=0.88) with no 
heterogeneity (I2=0%) (Fig 4). Individual RCTs reported a DRM rate of 0%-1.6% for LARR 
and 0% to 1.8% for ORR. Furthermore, the weighted mean difference in the distance to the 
DRM reported by 7 RCTs25-31 showed comparable results for LARR and ORR validating the 
technical equivalency for both surgical procedures.  
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Lymph node harvesting (LNH) 
Lymph node metastasis informs prognosis and is a crucial factor in determining whether 
added treatment such as adjuvant chemotherapy is needed following oncologic colorectal 
resection.  An established body of evidence exists, demonstrating an association between a 
higher total LN count and improved survival, mainly for node negative colorectal cancer. 
Current guidelines recommend a minimum of 12 nodes harvested as the standard of care, yet 
the evidence for such is doubtful as it is uncertain whether increasing the LN count results in 
improved survival45. The number of lymph nodes in surgical resection specimens is 
influenced by numerous factors. Good oncologic dissection techniques by surgeons (both for 
LARR and ORR) and methodical dissection by the pathologists are the two vital factors to 
maximize lymph node yields46. Other factors which influence the LNH include neoadjuvant 
treatment, old age, early stage and low-grade cancer. LNH was reported by 12 RCTs19-28,30,31 
(Fig 5). The mean number of LNs obtained in the surgical specimen varied between 5 to 19 
for LARR18,21 and 7 to 19 for ORR21,26. The majority of contemporary large RCTS24,28,30,31 had 
a lymph node yield in excess of 12 for both LARR and ORR. However, this was not true for 
other RCT enrolling more than 100 patients in each arm26, where the yield was quite poor 
(Fig 5). The pooled data for this variable showed no difference between the LARR and ORR 
for LNH (p=0.59) with substantial heterogeneity (I2=84.66%). Whether such a large variation 
in LNH for both procedures should be used as a surrogate marker of quality of surgery and 
standard of care for patient require further debate47.  
 
Length of Resected Specimen 
Surgical specimen length following colorectal resection is said to correlate with the number of 
harvested lymph nodes48,49. Stracci et al48 has suggested specimen lengths <20 cm were 
associated with a high risk of inadequate lymph node counts/retrieval which may lead to 
unnecessary over-treatment of those patients with a lymph node count of <10 e.g. with 
chemotherapy. This variable was reported by only four studies18,26,29,30 although only 3 were 
analyzable. Two out of three RCTs29,30 have shown the total length of resected specimen to be 
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> 20cm. Fleshman’s RCT30 showed a linear relationship with the length of the specimen and 
higher LNH, although this was surprisingly not the case with Stevenson et al RCT29. The third 
RCT26 showed resected specimens to be <20 cm and much smaller lymph node harvesting i.e. 
<10 for both LARR and ORR. The pooled data was comparable between LARR and ORR 
(p=0.79) with no heterogeneity (I2 = 0.00 %). In the future RCTs, mandatory reporting of the 
length of the specimen should be a criterion to gauge its effect on the number of LNH.   
 
Tumor Size 
Tumor size seems to have independent and important prognostic value in colorectal cancer. A 
recent study by Chen et al50 undertook a critical reappraisal of the value of tumor size as a 
prognostic variable in rectal adenocarcinoma and found a pathological tumor size of ≥5 cm to 
be an independent prognostic factor for local recurrence in their patients. They revealed the 5-
year overall survival rates in patients having tumors measuring <5 cm and ≥5 cm in size were 
82.60% and 71.20%, respectively (log-rank, P = 0.001). In our meta-analysis 6 studies 
reported tumor size 19,26-30. Only one RCT19 reported rectal tumor size of > 5 cm both for 
LARR and ORR. The rest of the RCTs had tumor size between 2.2 cm to 4.2 cm in LARR 
and 2.4 cm to 4.3 cm in ORR (Fig 6). Long term data is eagerly awaited to see if there is a 
direct correlation between larger tumor size, local and distant recurrence and death in these 
RCTs.  
 
Perforated Rectum 
Four RCTs19,23,27,30 have provided data on this variable and it favors ORR (91%) compared to 
LARR (84.6%) (p=0.05) with no heterogeneity (I2 = 0.00 %) (Fig 7). However, none of these 
RCTs have provided detail analysis of their perforated patients such as correlation to the 
position (anterior, posterior or circumferential) or location (upper, middle or lower third) of 
tumor, histological grade (T1-T4), previous chemoradiation, APR etc which would have been 
of immense important. Other larger RCTs such as COLOUR II31, COREAN28 and the 
ALaCaRT29 have not made any attempt to provide this data which has a significant bearing on 
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the local recurrence in the pelvis, distant recurrence, overall survival and cancer specific 
survival. It would be hard to believe that none of these RCTs suffered from iatrogenic rectal 
perforation in some of their patients. One of the landmark papers published in 199051 showed 
iatrogenic inadvertent rectal perforation occurred in 8.7% in rectal carcinoma patients. Other 
studies have similarly address the issue of rectal perforation rate and its impact on local 
recurrence and overall survival52-54. The rectal perforation rate however, seems to be higher in 
Fleshman’s RCT30 especially for LARR which is 15.4% compared to 9% for ORR.  
 
Rectal perforation seems to be more prevalent in abdominoperineal resections (APR). Holm 
et al55 therefore described the extended posterior perineal approach for the APR resulting in a 
lower risk of bowel perforation and CRM involvement. They selected those patients in whom 
a MRI scan indicated a T3–4 tumour within 6 cm of the anal verge or a low tumor fixed or 
tethered at rectal examination55. In practice, the APR is more difficult in the smaller pelvis of 
male patients and in tumors growing anteriorly where the distance to the mesorectal fascia is 
smallest. Other factors which can decrease the CR  involvement and perforation rate and 
thus improve both local control and overall survival include chemoradiotherapy and delayed 
surgery. This approach seems to downstage and downsize tumours56,57. Lower perforation rate 
decreases the intraoperative tumor cell spillage which has a positive effect on survival rates. 
In a study by Zirngible et al51, intraoperative spillage of tumor cells led to a significantly 
higher local recurrence of 39% as opposed to 12.9% without perforation or incision of the 
tumor. Furthermore, intraoperative tumor-cell spillage reduced the relative five-year survival 
rate after curative resection from 70% to 44 %. These authors emphasized the need to record 
this complication in the surgical and pathologic reports and consider it in the analysis of 
treatment results and in the selection of patients for adjuvant radiotherapy. Bulow et al on 
behalf of the Danish Colorectal Cancer Group58 published the results of intra-operative 
perforation in 108/1125 patients (10%) following APR for rectal cancer. According to them 
iatrogenic rectal perforation was a major risk factor for local and distant recurrence and 
overall survival and therefore should be avoided. Similarly, another study from Norway54 
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undertook analysis of their prospective national database of 2873 patients undergoing major 
resection of rectal carcinoma at 54 Norwegian hospitals from November 1993 to December 
1999. The overall perforation rate was 8.1% (234 of 2873 patients). In a multivariate analysis, 
the risk of perforation was significantly greater in patients undergoing abdominoperineal 
resection and in those aged 80 years or more. The 5-year local recurrence rate was 28.8 % 
following perforation, compared with 9.9% in patients with no perforation (P<0.001); 
survival rates were 41.5% and 67.1% respectively (P<0.001).  All these studies serve as a 
reminder to record this complication methodically both in operative and pathologic reports 
and not just to monitor the 5 and 10-year recurrence free survival and overall survival as these 
patients will most likely require additional therapies such as adjuvant chemoradiation to 
reduce the risk of recurrence and improve overall survival. The analysis of the cohort of 
perforated rectal patients in Fleshman et al’s RCT30 in the coming years would provide us a 
better idea of the outcome of these patients compared to those without such perforations.  
 
RECOMMENDATIONS AND CONCLUSIONS  
1. LARR for rectal cancer is an evolving technique and seems to be feasible but its oncologic 
safety is not completely determined and as such remains a contentious issue. 
 
2. There is a significantly higher iatrogenic rectal perforation rate for LARR compared to 
ORR, albeit based on one larger RCT as no other trails have reported this to date. It is 
therefore imperative that surgeons should keep a strict record of rectal perforation for both 
LARR and ORR to tailor the postoperative treatment. All the future RCTs should include this 
as part of the dataset. 
 
3. Except for the COLOR II study, no other RCT has published the 3-year data on 
locoregional recurrence, and disease free and overall survival, which appears to be 
comparable for both LARR and ORR. However, as no separate data on rectal perforation 
patients is available in COLOR II and other RCTs, it would be worth undertaking a subgroup 
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analysis of these patients to determine their fate over the next 3, 5 and 10 years.  
 
4. As there exists no consistent protocol for CRM and DRM amongst the various RCTs, this 
should be standardized for all future RCTs to clearly determine the effects of these two 
variables in terms of local recurrence and the use of adjuvant therapies.  
 
5. Once again the issue of specimen length and its impact on lymph node harvesting has not 
been addressed in any of the RCTs. This should be considered, at the very minimum, to be 
part of the data set in all the future RCTs as this may impact the disease free and overall 
survival.   
 
6. There is a direct correlation between larger tumor size, local and distant recurrence and 
death in these patients. Therefore, the size of the rectal tumor should be recorded in future 
RCTs.  
 
Based on this meta-analysis and its limitations, LARR compares favorably to ORR for rectal 
cancer treatment in terms of completeness of TME, +ve CRM, +ve DMR, lymph nodes 
harvesting; length of resected specimen and tumor size. However, there is a significantly 
higher risk of rectal perforation during LARR compared to ORR which is concerning in terms 
of oncological adequacy and safety. In view of all these above mentioned issues, LARR 
should only be performed in established high volume colorectal units by experienced 
laparoscopic surgeon. Furthermore, it is imperative that some of the above-mentioned issues 
should be standardized for a more accurate comparison of the data from various colorectal 
units especially the ones who are undertaking RCTs.   
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FIGURE LEGENDS 
Figure 1: PRISMA flow diagram 
Figure 2: Forrest and funnel plots for complete TMR 
Figure 3: Forrest and funnel plots for positive CRM 
Figure 4: Forrest and funnel plots for positive DRM 
Figure 5: Forrest and funnel plots for lymph node harvest 
Figure 6: Forrest and funnel plots for tumor size 
Figure 7: Forrest and funnel plots for perforated rectum 
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Table 1: Silent features of RCTs          
Author/Year/ Country 
Study 
Design 
Total 
Patients LARR ORR Follow-up LARR ORR 
Enrollment 
Period JADAD score 
n n  n months n (%) n (%)  R B DO Total 
M:F M:F      
Bonjer et al 2015/Netherlands31 RCT 1044 
699 
448:251 
345 
211:134 60 699 (67) 345 (33) 2004 and 2010 2 0 1 3 
Fleshman et al 2015/USA30 RCT 481 
242 
156:86 
239 
158:81 To date 240 (52) 239 (48) 2008 and 2013 1 0 1 2 
Stevenson et al 2015/Australia29 RCT 473 
238 
160:78 
235 
151:84 To date 238 (50) 235(50) 2010 to 2014 2 1 1 4 
Jeong et al 2014/South Korea28 RCT 340 
170 
110:60 
170 
110:60 36 170 (50) 170 (50) 2006 to 2009 2 0 1 3 
Ng et al 2014/Hong Kong27 RCT 80 
40 
24:16 
40 
22:18 75 40 (50) 40 (50) 2001 and 2007 2 0 1 3 
Liang et al 2011/China26 RCT 343 
169 
104:65 
174 
92:82 
44 
(median) 169 (49) 174(51) 2004 and 2008 2 0 1 3 
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Liu et al 2010/China25 RCT 186 
98 
56:42 
88 
50:38 
16.3 
(mean) 98 (53) 88(47) 2005 and 2008 2 0 1 3 
Lujan et al 2009/Spain24 RCT 204 
101 
62:39 
103 
64:39 
34·1 
(mean) 101 (49.5) 103(50.5) 2002 and 2007 2 0 1 3 
Ng et al 2009/Hong Kong23 RCT 153 
76 
37:39 
77 
48:29 120 76 (50) 77 (50) 1993 to 2002 2 0 1 3 
Ng et al 2008/Hong Kong22 RCT 99 
51 
31:20 
48 
30:18 
Approx 90 
(median) 51 (51.5) 48 (48.5) 1994 and 2005 2 0 1 3 
Pechlivanides et al 
2007/Greece21 RCT 73 
34 
20:14 
39 
23:16 N/A 34 (470 39 (53) N/A 2 0 0 3 
Braga et al 2006/Italy20 RCT 168 
83 
55:28 
85 
64:21 53.6 83 (49) 85 (51) N/A 2 0 1 3 
Zhou et al 2004/China19 RCT 171 
82 
46:36 
89 
43:46 1-16 82 (48%) 89 (52%) 2001 and 2002 2 0 1 3 
Araujo et al 2003/Brazil18 RCT 28 
13 
9:4 
15 
10:5 47 (mean) 13(46.4) 18(53.6) 1997 and 2000 2 0 1 3 
B= Blinding; DO= Drop outs; F= Female; LARR= Laparoscopic assisted rectal resection; M= Male; n (%)= number (percentage); ORR= Open rectal resection; R= Randomization; 
RCT= Randomized controlled trial 
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Table 2: Silent feature of histopathological variables analyzed using the random effect method in R using metafor package 
Outcome variables 
RCTs Patients Pooled Data Test for Overall Effect Test for Heterogeneity 
  OR or WMD* [95%CI] Z (p-value) Q (p-value)  [95% CI] 
TME complete 6 2570 0.77 [0.56,1.07] -1.54 (0.12) 5.70 (0.336) 13.61 [0.00,90.40] 
TME incomplete 6 2570 1.15 [0.83,1.59] 0.82 (0.41) 4.72 (0.451) 0.00 [0.00,87.22] 
+CRM 12 3297 1.21 [0.88,1.67] 1.19 (0.24) 6.03 (0.872) 4.88 [0.00,24.83] 
-CRM 12 3297 0.82 [0.60,1.13] -1.19 (0.24) 6.03 (0.872) 4.88 [0.00,24.83] 
+DRM  8 2084 1.08 [0.42,2.75] 0.15 (0.88) 0.31 (1.000) 0.00 [NA,NA] 
Distance to the DRM 7 2812 0.5* [-1.56,2.55] 0.47 (0.64) 19.64 (0.003) 72.10 [24.22,94.41] 
Lymph node harvesting 12 3180 0.30* [-0.81,1.41] 0.53 (0.59) 126.66 (0.000) 84.66 [65.21,96.63] 
Length of resected Specimen 3 1278 0.60* [-3.74,4.95] 0.27 (0.79) 0.80 (0.671) 0.00 [0.00,72.76] 
Tumor size 6 1825 -0.73* [-2.14,0.67] -1.02 (0.31) 4.41 (0.492) 0.00 [0.00,85.64] 
Perforated Rectum 4 866 1.71 [1.01,2.89] 2.01 (0.04) 0.26 (0.967) 0.00 [0.00,27.14] 
Intact Rectum  4 866 0.59 [0.35,0.99] -2.01 (0.04) 0.26 (0.967) 0.00 [0.00,27.14] 
CI= Confidence Interval; CRM= Circumferential Resection Margin; DRM= Distal Resection Margin; I2= I square statistic; k= number of studies; n= number of patients; OR= Odds 
Ratio; Q= Q Statistic; RCTs= Randomized Controlled Trials; TME= Total Mesorectal Excision; WMD= Weighted Mean Difference; Z= Z statistics or score 
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Table 1: Silent features of RCTs          
Author/Year/ Country 
Study 
Design 
Total 
Patients LARR ORR Follow-up LARR ORR 
Enrollment 
Period JADAD score 
n n  n months n (%) n (%)  R B DO Total 
M:F M:F      
Bonjer et al 2015/Netherlands31 RCT 1044 
699 
448:251 
345 
211:134 60 699 (67) 345 (33) 2004 and 2010 2 0 1 3 
Fleshman et al 2015/USA30 RCT 481 
242 
156:86 
239 
158:81 To date 240 (52) 239 (48) 2008 and 2013 1 0 1 2 
Stevenson et al 2015/Australia29 RCT 473 
238 
160:78 
235 
151:84 To date 238 (50) 235(50) 2010 to 2014 2 1 1 4 
Jeong et al 2014/South Korea28 RCT 340 
170 
110:60 
170 
110:60 36 170 (50) 170 (50) 2006 to 2009 2 0 1 3 
Ng et al 2014/Hong Kong27 RCT 80 
40 
24:16 
40 
22:18 75 40 (50) 40 (50) 2001 and 2007 2 0 1 3 
Liang et al 2011/China26 RCT 343 
169 
104:65 
174 
92:82 
44 
(median) 169 (49) 174(51) 2004 and 2008 2 0 1 3 
Liu et al 2010/China25 RCT 186 98 88 16.3 98 (53) 88(47) 2005 and 2008 2 0 1 3 
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56:42 50:38 (mean) 
Lujan et al 2009/Spain24 RCT 204 
101 
62:39 
103 
64:39 
34·1 
(mean) 101 (49.5) 103(50.5) 2002 and 2007 2 0 1 3 
Ng et al 2009/Hong Kong23 RCT 153 
76 
37:39 
77 
48:29 120 76 (50) 77 (50) 1993 to 2002 2 0 1 3 
Ng et al 2008/Hong Kong22 RCT 99 
51 
31:20 
48 
30:18 
Approx 90 
(median) 51 (51.5) 48 (48.5) 1994 and 2005 2 0 1 3 
Pechlivanides et al 
2007/Greece21 RCT 73 
34 
20:14 
39 
23:16 N/A 34 (470 39 (53) N/A 2 0 0 3 
Braga et al 2006/Italy20 RCT 168 
83 
55:28 
85 
64:21 53.6 83 (49) 85 (51) N/A 2 0 1 3 
Zhou et al 2004/China19 RCT 171 
82 
46:36 
89 
43:46 1-16 82 (48%) 89 (52%) 2001 and 2002 2 0 1 3 
Araujo et al 2003/Brazil18 RCT 28 
13 
9:4 
15 
10:5 47 (mean) 13(46.4) 18(53.6) 1997 and 2000 2 0 1 3 
B= Blinding; DO= Drop outs; F= Female; LARR= Laparoscopic assisted rectal resection; M= Male; n (%)= number (percentage); ORR= Open rectal resection; R= 
Randomization; RCT= Randomized controlled trial 
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Table 2: Silent feature of histopathological variables analyzed using the random effect method in R using metafor package 
Outcome variables 
RCTs Patients Pooled Data Test for Overall Effect Test for Heterogeneity 
  OR or WMD* [95%CI] Z (p-value) Q (p-value)  [95% CI] 
TME complete 6 2570 0.77 [0.56,1.07] -1.54 (0.12) 5.70 (0.336) 13.61 [0.00,90.40] 
TME incomplete 6 2570 1.15 [0.83,1.59] 0.82 (0.41) 4.72 (0.451) 0.00 [0.00,87.22] 
+CRM 12 3297 1.21 [0.88,1.67] 1.19 (0.24) 6.03 (0.872) 4.88 [0.00,24.83] 
-CRM 12 3297 0.82 [0.60,1.13] -1.19 (0.24) 6.03 (0.872) 4.88 [0.00,24.83] 
+DRM  8 2084 1.08 [0.42,2.75] 0.15 (0.88) 0.31 (1.000) 0.00 [NA,NA] 
Distance to the DRM 7 2812 0.5* [-1.56,2.55] 0.47 (0.64) 19.64 (0.003) 72.10 [24.22,94.41] 
Lymph node harvesting 12 3180 0.30* [-0.81,1.41] 0.53 (0.59) 126.66 (0.000) 84.66 [65.21,96.63] 
Length of resected Specimen 3 1278 0.60* [-3.74,4.95] 0.27 (0.79) 0.80 (0.671) 0.00 [0.00,72.76] 
Tumor size 6 1825 -0.73* [-2.14,0.67] -1.02 (0.31) 4.41 (0.492) 0.00 [0.00,85.64] 
Perforated Rectum 4 866 1.71 [1.01,2.89] 2.01 (0.04) 0.26 (0.967) 0.00 [0.00,27.14] 
Intact Rectum  4 866 0.59 [0.35,0.99] -2.01 (0.04) 0.26 (0.967) 0.00 [0.00,27.14] 
CI= Confidence Interval; CRM= Circumferential Resection Margin; DRM= Distal Resection Margin; I2= I square statistic; k= number of studies; n= number of patients; 
OR= Odds Ratio; Q= Q Statistic; RCTs= Randomized Controlled Trials; TME= Total Mesorectal Excision; WMD= Weighted Mean Difference; Z= Z statistics or score 
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• Laparoscopic assisted rectal resection (LARR) continued to be one of the most technically 
challenging operations in the laparoscopic era and its benefit for rectal cancer remains 
contentious. 
 
• Concerns regarding long term equivalence of conventional open rectal resection (ORR) 
versus LARR are still under debate due to lack of longitudinal data on many RCTs. 
 
• The present meta-analysis and systematic review utilizing only randomized evidence was 
undertaken to evaluate the histopathological differences between ORR and LARR for rectal 
cancers. 
 
• The oncologic safety of LARR is not completely determined especially as there is a higher 
risk of iatrogenic rectal perforation compared to its ORR counterpart and as such remains a 
controversial issue. 
 
• Based on our systematic review and meta-analysis, we believe that LARR should only be 
performed in established high volume colorectal units and cannot be justified outside the 
setting of clinical trials. 
 
